Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Kite Pharma’s CAR-T Clinical Trial To Use Chemotherapy Drug Implicated In Patient Deaths

XTALKS VITALS NEWS

Chemotherapy

The study is set to use both cyclophosphamide and fludarabine as preconditioning agents, though Kite says they will be administered at much lower doses than they were in the Juno trial.

Tweetables from this article:

Tweet: Kite Pharma plans to use low-dose fludarabine as a preconditioning agent  http://ctt.ec/tCdr2+Kite Pharma plans to use low-dose fludarabine as a preconditioning agent .

Tweet: Kite Pharma has already enrolled 72 patients in Phase II clinical trial http://ctt.ec/eMlN2+Kite Pharma has already enrolled 72 patients in Phase II clinical trial .

Share this!

July 15, 2016 | by Sarah Massey, M.Sc.

In its upcoming clinical trial of their CAR-T therapy, Kite Pharma plans to use low-dose fludarabine as a preconditioning agent – a drug implicated in the death of three patients in a similar study conducted by Juno Therapeutics. Following the deaths, both Juno and the US Food and Drug Administration (FDA) decided to cease using fludarabine for the remainder of the company’s clinical trial.

The FDA issued a brief clinical hold on Juno’s Phase II CAR-T study last week while the cause of the patient deaths were being investigated. Once the company had submitted the necessary information to the regulator, the ROCKET study was allowed to continue without the use of fludarabine.

Just hours after the Juno trial was stopped, Kite announced they had already enrolled 72 patients with certain blood cancers in their Phase II clinical trial of their candidate, KTE-C19. The study is set to use both cyclophosphamide and fludarabine as preconditioning agents, though Kite says they will be administered at much lower doses than they were in the Juno trial.



“Kite Pharma’s announcement regarding the enrollment of the 72nd patient marks a significant milestone in our ZUMA 1 trial,” a spokesperson for Kite Pharma told FierceBiotech. This trial is the culmination of over 10 years of study and testing where Kite and our NCI collaborators have carefully examined every aspect of CAR-T therapy including the optimal dose pre-conditioning regimen of cyclophosphamide and fludarabine and the KTE-C19 cell dose.

“Our analysis has been methodical and systematic and included dose ranging studies and a Phase I run-in to the ZUMA studies of diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL),” the spokesperson continued. “Kite’s clinical program is ongoing with data anticipated from the ZUMA 1 trial later this year.”

According to analysts at Jefferies, there have now been four patient deaths as a result of Juno’s clinical trial – a statement that has so far not been confirmed by Juno. While Juno’s shares were impacted after the trial was put on hold, they have since rebounded as the study is now allowed to continue.


Keywords: CAR-T, FDA, Clinical Trial


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.